Cover Image

2023 medicinal chemistry reviews /

"Medicinal Chemistry Reviews (MCR) furnishes readers with a clear and succinct account of significant developments published during the past two to three years in major fields within medicinal chemistry. The chapters are not intended to be exhaustive but should provide the reader with ample lea...

Full description

Bibliographic Details
Corporate Authors: American Chemical Society, American Chemical Society. Division of Medicinal Chemistry
Other Authors: Rudolph, Joachim (Editor), Bronson, Joanne J. (Editor)
Format: eBook
Language:English
Published: Washington, DC, USA : American Chemical Society, 2023.
Series:Medicinal Chemistry Reviews, Vol. 58.
Subjects:
Pharmaceutical chemistry.
Clinical chemistry.
Chemistry, Pharmaceutical
Chemistry, Clinical
Chimie pharmaceutique.
Chimie clinique.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Contributors
  • Preface
  • 1. My Career in Medicinal Chemistry / John A. Lowe, III
  • 2. You Can't Always Get What You Want. But if You Try Sometimes, You Get What You Need: Insights from My Unlikely Career in Drug Development / Dennis Liotta
  • Section 1: Central Nervous System Diseases, Neuroinflammation, and Pain Section Editor / Emily A. Peterson, Corey R. Hopkins
  • 3. The Serotonin 5-HT2A Receptor as an Evolving Neurotherapeutic Target / Andrew A. Bolinger, Noelle C. Anastasio, Kathryn A. Cunningham, Jia Zhou
  • 4. Recent Developments in the Discovery of Brain-Penetrant RIP1 Inhibitors / Craig E. Stivala, Domagoj Vucic
  • Section 2: Cardiovascular, Metabolic, and Fibrotic Diseases / Section Editors: Johan D. Oslob, Antonio Romero
  • 5. Advances Toward an Oral Non-Peptide Agonist of the GLP-1 Receptor / Todd Fields, Eric M. Woerly, Michael G. Bell, Kyle W. Sloop, Joseph D. Ho
  • 6. Recent Advances in Small-Molecule Inhibitors of Ketohexokinase (KHK) / David C. Ebner, Gregory J. Tesz, Kentaro Futatsugi
  • Section 3: Immunologic, Inflammatory, and Respiratory Diseases / Section Editors: J. Michael Ellis, Jennifer D. Venable
  • 7. Targeting Selective Tyrosine Kinase 2 (TYK2) Inhibitors for the Treatment of Autoimmune Diseases / Silvana Leit, Bhaskar Srivastava, Nathan E. Genung, Joshua J.
  • 8. An Integrin Renaissance: Recent Progress of Integrin Modulators in the Clinic / Darren Finkelstein, Timothy D. Machajewski
  • 9. Salt-Inducible Kinases: An Emerging Target Class With Broad Therapeutic Potential / Nicolas Desroy, Christophe Peixoto, Steve De Vos
  • Section 4: Oncology / Section Editors: Jason Kettle, Scott D. Edmondson
  • 10. Small Molecule Degraders of Ikaros Zinc Finger (IKZF) Transcription Factors / Natalie Holmberg-Douglas, Hunter Shunatona, Godwin Kumi, Ashok Purandare
  • 11. Recent Advances in Targeting the PRMT5/MTA Complex / Christopher R. Smith, Matthew A. Marx
  • 12. Recent Advances in the Discovery of Cyclin-Dependent Kinase 2 (CDK2) Selective Inhibitors / Kevin D. Freeman-Cook, Robert L. Hoffman
  • Section 5: Infectious Diseases / Section Editors: William J. Watkins, Adam S. Duerfeldt
  • 13. Recent Advances in the Discovery of Antimicrobial Natural Products through Synthetic Means / M. Alejandro Valdes-Pena, Joshua G. Pierce
  • 14. Practical Applications of Machine Learning for Anti-Infective Drug Discovery Nishant Sarkar, Jonathan M. Stokes
  • 15. Recent Progress in Antivirals Against Zika Virus María-Jesús Pérez-Pérez, Eva-María Priego, Miguel A. Martín-Acebes
  • Section 6: Topics in Biology / Section Editors: John A. Lowe III, Amanda L. Garner
  • 16. Small-Molecule RNA-Splicing Modulators / Hasane Ratni, Kathleen D. McCarthy, Joseph L. Duffy, Sergey V. Paushkin, Sivaraman Dandapani
  • 17. Small-Molecule Interactions With Biomolecular Condensates / George S. Tria, Joseph W. Tucker, Mary E. Spilker, Brooke A. Conti, Mariano Oppikofer
  • Section 7: Topics in Drug Design and Discovery / Section Editors: Brad M. Savall, Matthew Bourbeau
  • 18. The Rise, Fall, and Future Promise of IDO1 Inhibitors for Immuno-Oncology / Emily C. Cherney, David K. Williams, Liping Zhang, Susheel J. Nara
  • 19. Drug-Induced Liver Injury: Mechanisms, Methods, Pre-Clincial Assessment, and a Medicinal Chemist's Perspective / Anh T. Tran, James J. Crawford, Debashis Mandal, Tezcan Guney, Jamie Karmel
  • 20. Non-Cyclic Dinucleotide STING Agonists for Immuno-Oncology / Julian C. Lo, Emily C. Cherney
  • Section 8: Case Histories and New Chemical Entities / Section Editors: Brian G. Lawhorn, Peter S. Dragovich
  • 21. Case History: Discovery and Development of Verquvo(R) (Vericiguat), a Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Chronic Heart Failure / Markus Follmann, Corina Becker, Lothar Roessig, Peter Sandner, Johannes-Peter Stasch
  • 22. Case History: Corectim(R) (Delgocitinib), The First Topical JAK Inhibitor for the Treatment of Atopic Dermatitis / Makoto Shiozaki
  • 23. New Chemical Entities Entering Phase III Trials in 2022 Matthew L. Condakes, Jennifer Jiang, David W. Lin, Rhiannon Thomas-Tran, Juan del Pozo, Christiana N.
  • 24. To Market, to Market-2022: Small Molecules / Erika Araujo, Ian M. Bell, Alexander Burckle, Dennis C. Koester, James R. Manning, Georgette Castanedo, Mingshuo Zeng, T. G. Murali Dhar, Natalie Holmberg-Douglas, Eric R. Welin, J. Robert Merritt, Kevin M. Peese, Joanne J. Bronson
  • 25. To Market, to Market-2022: Macromolecular Therapeutics / Shion A. Lim, Nicholas J. Agard, Ryan L. Kelly, Benjamin N. Bell, Si-Jie Chen, Anna M. Gram, J. Robert Merritt, Ian Moench, Katarina Pance, Tatjana Petojevic
  • Indices
  • Keyword Index, Volume 58
  • Cumulative NCE Introduction Index, 2014-22
  • Cumulative NCE Introduction Index (by Indication), 2014-22